News

The company posted a net loss of $8.75m, compared to a net loss of $7.31m for the same period in 2009. Trius’ loss from operations was $9m, as

Norethindrone and Ethinyl Estradiol, USP 0.4 mg/0.035 mg tablets are the generic version of Ovcon 35 tablets by Warner Chilcott. The product will be marketed under the trade

Valacyclovir Hydrochloride Tablets 500mg and 1 gram are the generic equivalent of Valtrex by GlaxoSmithKline. Actavis is a pharmaceutical company specializing in the development, manufacture and sale of

BioRelix is building a portfolio of anti-infective products based on novel patented RNA targets, termed riboswitches – an innovative class of RNA drug targets found in pathogenic bacteria

As per the agreement, Pozen has licensed Cilag to manufacture, develop and commercialize MT 400 as migraine drug. Pozen previously licensed US-only rights to MT 400 to GlaxoSmithKline,

Xoma 052, which is being jointly developed by Xoma and Servier, is a monoclonal antibody with the potential to improve the treatment of patients with a wide variety

The patent entitled: ‘Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors,’ protects NX002 and related compounds. Currently, NX002 is in preclinical development for the

Canbex said the award will further support the preclinical trials of the company’s VSN series of compounds. The company expects to initiate Phase I trial of VSN16R, company’s

Prolia, administered as a single subcutaneous injection of 60mg once every six months, specifically targets RANK Ligand, an essential regulator of osteoclasts (the cells that break down bone).